PECAM1 and neoplasm: The evaluation of the antitumoral effects of AuNR‐ECFCs was assessed also in the tumor masses with a double immunohistochemical analysis for CD31, highlighted with DAB staining (brown), and PCNA, highlighted with RED staining.